$AXGN

Axogen, Inc.

Axogen develops, licenses and commercializes technologies for peripheral nerve regeneration and repair, providing surgical products to surgeons and healthcare providers treating nerve injuries. Its portfolio includes Avance Nerve Graft, a processed human nerve allograft; Axoguard Nerve Connector, Nerve Protector, HA+ Nerve Protector and Nerve Cap, made from porcine extracellular matrix; and Avive+ Soft Tissue Matrix, an amniotic membrane allograft. The portfolio is available in the U.S., Canada, Germany, the United Kingdom, Spain and several other countries. Axogen makes money primarily by distributing and selling its nerve repair products. U.S. sales of Avance Nerve Graft, the Axoguard products and Avive+ Soft Tissue Matrix are its main sales contributor. Surgeons use the products in procedures to repair, protect or reconstruct peripheral nerves. Axogen is based in Alachua, Florida.

No enriched coverage for $AXGN in the last 7 days.

No SEC Form 4 filings for $AXGN in the last 30 days.

See all $AXGN insider activity →
Med

Axogen Advances Prostate Market Launch, Citing $754 Million U.S. TAM

Axogen plans to launch a prostate-market product, targeting a $754M U.S. market. The company estimates 110,000 annual prostatectomy cases with a $7,000 per-procedure price. Axogen's COAPT technique, using Avance nerve allograft, has shown 80% of patients with better-than-expected erectile function after six months. 88% of surveyed patients expressed interest in the procedure.

AXGN sentiment & insider activity

Recent AXGN coverage spans financial news, earnings and market movers.

What's driving AXGN

AlphAI scores every news story that mentions AXGN with an AI model for sentiment and relevance, and aggregates insider trades from Axogen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AXGN

Score

Axogen Advances Prostate Market Launch, Citing $754 Million U.S. TAM

Axogen plans to launch a prostate-market product, targeting a $754M U.S. market. The company estimates 110,000 annual prostatectomy cases with a $7,000 per-procedure price. Axogen's COAPT technique, using Avance nerve allograft, has shown 80% of patients with better-than-expected erectile function after six months. 88% of surveyed patients expressed interest in the procedure.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$AXGNHighAI 8/10

AxoGen Q3 2026 slides: revenue surges 26%, breast growth accelerates

AxoGen (AXGN) reported Q3 2026 revenue of $75.8M, up 26.2% YoY, and raised its full-year outlook. The company saw strong growth in breast reconstruction and achieved near-universal payer coverage for its Avance Nerve Graft. GAAP net income was $2.3M, or $0.04 per share, while adjusted net income was $13.1M, or $0.21 per share. AxoGen holds $350.1M in cash with no debt and expects revenue of at least $290M for 2026.

$AXGNHighAI 8/10Earnings

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million ALACHUA and TAMPA, FL – October 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical

AxoGen stock initiated at Buy by BofA on growth outlook

BofA Securities initiated coverage on AxoGen (NASDAQ:AXGN) with a Buy rating and a $52.00 price target, citing 44% upside potential. The company, a leader in peripheral nerve repair, reported 23.6% revenue growth and a 74.6% gross margin. Near-term catalysts include a prostate market decision and potential coverage expansions. AxoGen recently completed a $208.7 million share offering and acquired BioCircuit, with mixed analyst reactions.

Related tickers